The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial

Affiliations

• ¹ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.
• ² Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
• ³ Department of Surgery, University of Toronto, Toronto, ON, Canada.
• ⁴ Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
• ⁵ Division of Cardiology, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.
• ⁶ Department of Medicine, University of Toronto, Toronto, ON, Canada.
• ⁷ Department of Physiology, University of Toronto, Toronto, ON, Canada.
• ⁸ Department of Anesthesia, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.
• ⁹ Department of Anesthesia, University of Toronto, Toronto, ON, Canada.
• ¹⁰ Division of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.
• ¹¹ Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.
• ¹² Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
• ¹³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
• ¹⁴ Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada.
• ¹⁵ Division of Nephrology, University Health Network, Toronto, ON, Canada.